drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (TCR-T)
drug_description
Autologous, gene-edited TCR-engineered T-cell (TCR-T) therapy targeting the KRAS G12V neoantigen presented by HLA-A*11:01; infused T cells recognize KRAS G12V peptide–HLA on tumor cells and mediate cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-edited to express a T-cell receptor specific for the KRAS G12V neoantigen presented by HLA-A*11:01. After infusion, these TCR-T cells recognize the KRAS G12V peptide–HLA complex on tumor cells, become activated, and mediate MHC-restricted cytotoxicity (e.g., perforin/granzyme release and cytokine-driven killing).
drug_name
RE001 T cell
nct_id_drug_ref
NCT06545201